Fulgent Genetics (FLGT) Competitors

Fulgent Genetics logo
$24.00 -0.08 (-0.32%)
As of 03:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

FLGT vs. PGNY, GRDN, MD, ADUS, and NEO

Should you buy Fulgent Genetics stock or one of its competitors? Fulgent Genetics's main competitors and comparable companies include Progyny (PGNY), Guardian Pharmacy Services (GRDN), Pediatrix Medical Group (MD), Addus HomeCare (ADUS), and NeoGenomics (NEO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Fulgent Genetics compare to Progyny?

Fulgent Genetics (NASDAQ:FLGT) and Progyny (NASDAQ:PGNY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Progyny has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulgent Genetics$322.67M2.08-$60.51M-$3.09N/A
Progyny$1.29B2.09$58.52M$1.0933.50

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by company insiders. Comparatively, 9.9% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fulgent Genetics presently has a consensus target price of $25.00, suggesting a potential upside of 4.15%. Progyny has a consensus target price of $35.83, suggesting a potential downside of 1.88%. Given Fulgent Genetics' higher probable upside, equities analysts plainly believe Fulgent Genetics is more favorable than Progyny.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulgent Genetics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Progyny
0 Sell rating(s)
4 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.73

In the previous week, Progyny had 11 more articles in the media than Fulgent Genetics. MarketBeat recorded 15 mentions for Progyny and 4 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 0.84 beat Progyny's score of 0.63 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fulgent Genetics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Progyny
5 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Progyny has a net margin of 6.80% compared to Fulgent Genetics' net margin of -27.53%. Progyny's return on equity of 19.82% beat Fulgent Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fulgent Genetics-27.53% -5.66% -5.16%
Progyny 6.80%19.82%12.75%

Fulgent Genetics has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Progyny has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Summary

Progyny beats Fulgent Genetics on 12 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Guardian Pharmacy Services?

Fulgent Genetics (NASDAQ:FLGT) and Guardian Pharmacy Services (NYSE:GRDN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Fulgent Genetics has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.Comparatively, Guardian Pharmacy Services has a beta of 0.06, suggesting that its share price is 94% less volatile than the broader market.

Guardian Pharmacy Services has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulgent Genetics$322.67M2.08-$60.51M-$3.09N/A
Guardian Pharmacy Services$1.45B2.19$49.22M$1.1742.83

48.1% of Fulgent Genetics shares are held by institutional investors. 36.2% of Fulgent Genetics shares are held by company insiders. Comparatively, 33.0% of Guardian Pharmacy Services shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Fulgent Genetics had 1 more articles in the media than Guardian Pharmacy Services. MarketBeat recorded 4 mentions for Fulgent Genetics and 3 mentions for Guardian Pharmacy Services. Fulgent Genetics' average media sentiment score of 0.84 beat Guardian Pharmacy Services' score of 0.42 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fulgent Genetics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Guardian Pharmacy Services
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Fulgent Genetics presently has a consensus target price of $25.00, indicating a potential upside of 4.15%. Guardian Pharmacy Services has a consensus target price of $45.57, indicating a potential downside of 9.07%. Given Fulgent Genetics' higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than Guardian Pharmacy Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulgent Genetics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Guardian Pharmacy Services
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Guardian Pharmacy Services has a net margin of 5.13% compared to Fulgent Genetics' net margin of -27.53%. Guardian Pharmacy Services' return on equity of 30.29% beat Fulgent Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fulgent Genetics-27.53% -5.66% -5.16%
Guardian Pharmacy Services 5.13%30.29%16.86%

Summary

Guardian Pharmacy Services beats Fulgent Genetics on 10 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Pediatrix Medical Group?

Pediatrix Medical Group (NYSE:MD) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

97.7% of Pediatrix Medical Group shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 1.8% of Pediatrix Medical Group shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Pediatrix Medical Group has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

Pediatrix Medical Group has a net margin of 7.66% compared to Fulgent Genetics' net margin of -27.53%. Pediatrix Medical Group's return on equity of 20.12% beat Fulgent Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pediatrix Medical Group7.66% 20.12% 8.14%
Fulgent Genetics -27.53%-5.66%-5.16%

In the previous week, Pediatrix Medical Group had 3 more articles in the media than Fulgent Genetics. MarketBeat recorded 7 mentions for Pediatrix Medical Group and 4 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 0.84 beat Pediatrix Medical Group's score of 0.06 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pediatrix Medical Group
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fulgent Genetics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pediatrix Medical Group presently has a consensus price target of $28.00, suggesting a potential downside of 10.71%. Fulgent Genetics has a consensus price target of $25.00, suggesting a potential upside of 4.15%. Given Fulgent Genetics' higher probable upside, analysts plainly believe Fulgent Genetics is more favorable than Pediatrix Medical Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pediatrix Medical Group
1 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Fulgent Genetics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Pediatrix Medical Group has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Pediatrix Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pediatrix Medical Group$1.91B1.28$165.39M$1.8417.04
Fulgent Genetics$322.67M2.08-$60.51M-$3.09N/A

Summary

Pediatrix Medical Group beats Fulgent Genetics on 11 of the 16 factors compared between the two stocks.

How does Fulgent Genetics compare to Addus HomeCare?

Addus HomeCare (NASDAQ:ADUS) and Fulgent Genetics (NASDAQ:FLGT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

95.4% of Addus HomeCare shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 4.1% of Addus HomeCare shares are held by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Addus HomeCare has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Addus HomeCare$1.42B1.60$95.91M$6.0020.34
Fulgent Genetics$322.67M2.08-$60.51M-$3.09N/A

In the previous week, Addus HomeCare had 22 more articles in the media than Fulgent Genetics. MarketBeat recorded 26 mentions for Addus HomeCare and 4 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 0.84 beat Addus HomeCare's score of 0.30 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Addus HomeCare
10 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fulgent Genetics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Addus HomeCare has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Addus HomeCare currently has a consensus target price of $137.11, indicating a potential upside of 12.37%. Fulgent Genetics has a consensus target price of $25.00, indicating a potential upside of 4.15%. Given Addus HomeCare's stronger consensus rating and higher probable upside, equities analysts plainly believe Addus HomeCare is more favorable than Fulgent Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Addus HomeCare
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75
Fulgent Genetics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Addus HomeCare has a net margin of 7.39% compared to Fulgent Genetics' net margin of -27.53%. Addus HomeCare's return on equity of 10.22% beat Fulgent Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Addus HomeCare7.39% 10.22% 8.01%
Fulgent Genetics -27.53%-5.66%-5.16%

Summary

Addus HomeCare beats Fulgent Genetics on 13 of the 17 factors compared between the two stocks.

How does Fulgent Genetics compare to NeoGenomics?

NeoGenomics (NASDAQ:NEO) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

In the previous week, Fulgent Genetics had 3 more articles in the media than NeoGenomics. MarketBeat recorded 4 mentions for Fulgent Genetics and 1 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 1.40 beat Fulgent Genetics' score of 0.84 indicating that NeoGenomics is being referred to more favorably in the media.

Company Overall Sentiment
NeoGenomics Positive
Fulgent Genetics Positive

NeoGenomics presently has a consensus price target of $20.88, suggesting a potential upside of 38.02%. Fulgent Genetics has a consensus price target of $25.00, suggesting a potential upside of 4.15%. Given NeoGenomics' stronger consensus rating and higher possible upside, equities research analysts plainly believe NeoGenomics is more favorable than Fulgent Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeoGenomics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.58
Fulgent Genetics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 1.1% of NeoGenomics shares are owned by company insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Fulgent Genetics has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeoGenomics$727.33M2.69-$108.03M-$0.25N/A
Fulgent Genetics$322.67M2.08-$60.51M-$3.09N/A

NeoGenomics has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

NeoGenomics has a net margin of -4.10% compared to Fulgent Genetics' net margin of -27.53%. NeoGenomics' return on equity of -0.99% beat Fulgent Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
NeoGenomics-4.10% -0.99% -0.59%
Fulgent Genetics -27.53%-5.66%-5.16%

Summary

NeoGenomics beats Fulgent Genetics on 12 of the 16 factors compared between the two stocks.

Get Fulgent Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FLGT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FLGT vs. The Competition

MetricFulgent GeneticsHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$671.12M$10.57B$7.73B$11.61B
Dividend YieldN/A2.54%2.46%4.43%
P/E Ratio-7.7735.8034.1629.83
Price / Sales2.082.088.475.65
Price / CashN/A23.3421.9322.50
Price / Book0.683.594.373.65
Net Income-$60.51M$332.46M$3.52B$392.18M
7 Day Performance-6.89%-4.09%-5.48%-4.27%
1 Month Performance21.17%-1.81%-4.62%-6.75%
1 Year Performance-16.69%18.67%-1.57%-7.22%

Fulgent Genetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FLGT
Fulgent Genetics
2.0081 of 5 stars
$24.00
-0.3%
$25.00
+4.2%
-17.3%$671.12M$322.67MN/A1,315
PGNY
Progyny
2.3566 of 5 stars
$36.43
+1.3%
$35.33
-3.0%
+51.3%$2.80B$1.29B33.42856
GRDN
Guardian Pharmacy Services
1.6392 of 5 stars
$49.70
+5.7%
$45.57
-8.3%
+70.0%$2.47B$1.45B42.473,600
MD
Pediatrix Medical Group
2.263 of 5 stars
$31.55
+0.2%
$27.20
-13.8%
+37.4%$2.46B$1.91B17.154,315
ADUS
Addus HomeCare
3.3832 of 5 stars
$126.29
+3.2%
$134.70
+6.7%
+14.2%$2.36B$1.42B21.0550,659

Related Companies and Tools


This page (NASDAQ:FLGT) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners